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OBJECTIVE — Todeterminewhetherwomenwithgestationaldiabetesmellitus(GDM)have
an increased risk of cardiovascular disease (CVD) following pregnancy.
RESEARCH DESIGN AND METHODS — All women aged 20–49 years with live
births between April 1994 and March 1997 in Ontario, Canada, were identiﬁed. Women with
GDM were matched with 10 women without GDM and were followed for CVD.
RESULTS — The matched cohorts included 8,191 women with GDM and 81,262 women
withoutGDM.Meanageatentrywas31years,andmedianfollow-upwas11.5years.Thehazard
ratio for CVD events was 1.71 (95% CI 1.08–2.69). After adjustment for subsequent type 2
diabetes, the hazard ratio was attenuated (1.13 [95% CI 0.67–1.89]).
CONCLUSIONS — Young women with GDM had a substantially increased risk for CVD
compared with women without GDM. Much of this increased risk was attributable to
subsequent development of type 2 diabetes.
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G
estational diabetes mellitus (GDM)
is a common condition affecting
2–4% of pregnant women (1) and
is associated with adverse outcomes for
both the fetus and the mother. Previous
GDM is a major risk factor for type 2 dia-
betes, which occurs in 20–60% of af-
fected women within 5 years of the
pregnancy (2). Women with a history of
GDM are also at increased risk of other
cardiovascular risk factors, such as obe-
sity, hypertension, dyslipidemia, and the
metabolicsyndrome(3–5),aswellassub-
clinical atherosclerosis (6). Taken to-
gether, these ﬁndings suggest that GDM
identiﬁesapopulationofyoungwomenat
increased risk for cardiovascular disease
(CVD). We used population-based admin-
istrative data to determine whether women
with GDM have a heightened risk for CVD
compared with women without GDM and
whether any increase in risk is independent
of subsequent type 2 diabetes.
RESEARCH DESIGN AND
METHODS— We conducted a popu-
lation-based retrospective cohort study
using administrative databases from On-
tario, Canada, that included hospital dis-
chargeabstracts,physicianserviceclaims,
and demographic data. The Ontario Dia-
betes Database is a validated registry of
physician-diagnosed nongestational dia-
betes that is identiﬁed using these admin-
istrative data (7). Individuals are linked
between all data sources via a unique
health card number, which is reproduc-
ibly encrypted in all of these data sources.
Women aged 20–49 years who had a
hospitalization record indicating a live
birth between April 1994 and March
1997 were selected. For women who had
more than one birth during this period,
one birth was selected at random. Those
whohadpregestationaldiabetesoraCVD
event (as deﬁned below) in the prior 3
years were excluded.
Baseline characteristics were age at
delivery, region of residence, and socio-
economic status (measured as the neigh-
borhood income quintile). Subjects with
missing data were excluded. Women
were deﬁned as having GDM using an al-
gorithmanalogoustothatusedbytheval-
idated registry to exclude GDM: one
hospitalization record or two ambulatory
physician claims bearing the diagnosis of
diabetes or GDM between 120 days be-
fore and 180 days after delivery.
The primary outcome (CVD events)
was deﬁned as a hospitalization for acute
myocardial infarction, stroke, coronary
artery bypass, coronary angioplasty, or
carotid endarterectomy. The prespeciﬁed
secondary outcome (coronary artery dis-
ease [CAD] events) was hospitalization
for acute myocardial infarction, coronary
artery bypass, or coronary angioplasty.
Subsequent diagnosis with diabetes was
identiﬁed if the woman entered the dia-
betes registry postpartum. Although the
registry does not distinguish between
types, the majority of women developing
diabetes in this group would have type 2
diabetes. All women were followed until
March 2007, with censoring on death.
Subjects with GDM were matched
with 10 subjects without GDM based on
baseline characteristics. Kaplan-Meier
survival curves were constructed for both
outcomes. Cox proportional hazards re-
gression was used to model the associa-
tion of GDM with each outcome,
accounting for the matched design of the
study. For each outcome, an unadjusted
model and a model adjusting for subse-
quent diagnosis of diabetes as a time-
dependent covariate were built. The
assumption of proportionality was veri-
ﬁed by plotting log(–log[survival]) versus
log(time) to assess parallelism. The study
was approved by the institutional review
board of Sunnybrook Health Sciences
Centre.
RESULTS— There were 356,891 po-
tentially eligible women with live births
during the study period. However, 3,127
were excluded because of preexisting di-
abetes, and 43 were excluded because of
previous CVD. A further 2,036 were
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cioeconomic status. Of the remaining
351,685 subjects, 8,194 (2.3%) had
GDM during the index pregnancy. The
matched cohorts included 8,191 women
with GDM and 81,262 without GDM.
The mean age of both cohorts was 31
years.
The median follow-up time was 11.5
years. Diabetes developed during fol-
low-up in 2,214 (27.0%) of the women
with GDM and 2,596 (3.2%) of the
women without GDM. Event-free sur-
vival for both CVD and CAD events are
plotted in Fig. 1. Signiﬁcant associa-
tions were found between GDM and both
outcomes, but these associations were at-
tenuated following adjustment for subse-
quent diabetes.
CONCLUSIONS — Our study is the
ﬁrstofitskindtoshowthatyoungwomen
with GDM have a substantially increased
risk for CVD relative to women without
GDM. The subsequent development of
type 2 diabetes accounts for much of this
increased risk, which reinforces the vital
need for diabetes prevention strategies in
this high-risk population.
Our ﬁndings are consistent with a
cross-sectional study conducted by Carr
et al. (5), which reported that women
with a history of GDM had odds ratios for
CVD and CAD similar to those reported
here (1.85 and 1.58, respectively). How-
ever, this study was cross-sectional and
relied on retrospective self-report to as-
certain exposures and outcomes. In con-
trast, our cohort study used a more
rigorous end point assessment and fol-
lowed a much larger population of
women over many years.
Our study used administrative data
where clinical information, such as car-
diovascular risk factors, was unavailable.
Women with GDM exhibit chronic insu-
linresistance(8),whichisassociatedwith
a clustering of risk factors that are in the
causal pathway to CVD. Therefore,
women with GDM likely have very differ-
ent risk factor proﬁles than those without
GDM, and adjusting for these differences
mightobscureaclinicallyimportantasso-
ciation between GDM and CVD.
Insummary,womenwithGDMareat
increased risk for CVD events compared
with women without GDM, and much of
this risk is attributable to the subsequent
developmentoftype2diabetes.Asdiabe-
tes prevention interventions in women
with a history of GDM have also been
shown to slow progression of atheroscle-
rosis (9), this study highlights the impor-
tance of diabetes prevention for this high-
risk population.
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Figure 1—Kaplan-Meier survival curves for CVD and CAD events and hazard ratios (HRs)
derived from Cox proportional hazards regression.
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